Patents by Inventor Gregg B. Fields

Gregg B. Fields has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200181095
    Abstract: We describe the use of comparative structural analysis and structure-guided molecular design to develop potent and selective inhibitors (10d and (S)-17b) of matrix metalloproteinase 13 (MMP-13). We applied a three-step process, starting with a comparative analysis of the X-ray crystallographic structure of compound 5 in complex with MMP-13 with published structures of known MMP-13 inhibitor complexes followed by molecular design and synthesis of potent, but non-selective zinc-chelating MMP inhibitors (e.g., 10a and 10b). After demonstrating that the pharmacophores of the chelating inhibitors (S)-10a, (R)-10a, and 10b were binding within the MMP-13 active site, the Zn2+ chelating unit was replaced with non-chelating polar residues that bridged over the Zn2+ binding site and reach into a solvent accessible area.
    Type: Application
    Filed: June 6, 2018
    Publication date: June 11, 2020
    Applicants: Florida Atlantic University Board of Trustees, The Scripps Research Institute
    Inventors: Gregg B. FIELDS, William R. ROUSH, Jun Yong CHOI, Rita FUERST
  • Publication number: 20200062736
    Abstract: The invention provides methods for treating cancers, such as melanoma and/or metastatic melanoma, using compounds that interact with and/or inhibit cellular proteins lamin A/C, ATP-dependent RNA helicase DDX1 (DDX1), heterogeneous nuclear ribonuclear protein H1/H2 (hnRNP H2), and/or heterogeneous nuclear ribonuclear protein A2/B1 (hnRNP A2/B1). The invention additionally provides a method for identifying compounds active against melanoma cells.
    Type: Application
    Filed: December 15, 2017
    Publication date: February 27, 2020
    Applicants: NOVA SOUTHEASTERN UNIVERSITY, AUBURN UNIVERSITY, FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES, TORREY PINES INSTITUTE FOR MOLECULAR STUDIES
    Inventors: Dmitriy Minond, Gregg B. Fields, Marcello Giulianotti
  • Publication number: 20160053250
    Abstract: Matrix metalloproteinases (MMPs) compositions, inactive forms of MMPs (e.g. proMMPs), fragments, mutants, variants or combinations thereof. A pharmaceutical composition comprises one or more of the above in a pharmaceutical carrier. A composition comprises at least one of: a matrix metalloproteinase (MMP), an inactive MMP or a proenzyme (proMMP) thereof, wherein the matrix metalloproteinase (MMPs), inactive MMPs or proMMPs thereof, comprise: MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-11, MMP-12, MMP-13.MMP-14, MMP-15, MMP-16, MMP-17, MMP-18, MMP-19, MMP-20, MMP-21, MMP-23A, MMP-23B, MMP-24, MMP-25, MMP-26, MMP-27, MMP-28, active fragments, mutants, variants or any combinations thereof. The uses include isolation of cells, in particular stem cells, from tissues, dissociation of tissues, proteins and treatment of a variety of conditions.
    Type: Application
    Filed: April 4, 2014
    Publication date: February 25, 2016
    Inventors: Claudia ZYLBERBERG, Gregg B. FIELDS
  • Publication number: 20090062211
    Abstract: Isolation, synthesis and therapeutic use of conotoxin and conophan compounds and related compositions including a new class of conopeptides including the modified amino acid D-?-hydro-oxyvalinie (D-Hyv=V*) are described herein. These isolated peptides are the first known example of a naturally occurring polypeptide chain containing D-Hyv. The active peptides, termed ?-Hydroxyconophans are heavily hydroxylated small peptides. These peptides contain a definitive structural motif which is a double modification of the polypeptide chain (?-D-OH-Hyv-Trp).
    Type: Application
    Filed: April 10, 2008
    Publication date: March 5, 2009
    Applicant: FLORIDA ATLANTIC UNIVERSITY
    Inventors: Frank Mari, Gregg B. Fields
  • Publication number: 20080125354
    Abstract: Synthetic triple-helical peptides (THPs) are used for the design and synthesis of triple-helical transition state analog inhibitors. These inhibitors feature a phosphonate ester or phosphinic moiety in place of the scissle bond. These groups inhibit MMPs, and methods been developed for their convenient incorporation within a peptide sequence by solid-phase methods.
    Type: Application
    Filed: November 21, 2006
    Publication date: May 29, 2008
    Applicants: Florida Atlantic University, Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Gregg B. Fields, Robert Hammer
  • Publication number: 20040176303
    Abstract: Disclosed are methods and compositions for modulation of ion levels in cells. The compositions contain a new class of biologically active peptides derived from the venom of predatory marine snails of the species Conus gladiator and Conus mus. The active peptides, termed &ggr;-Hydroxyconophans are heavily hydroxylated small peptides. These peptides contain a definitive structural motif which is a double modification of the polypeptide chain in contiguous residues, i.e., &ggr;-OH-Hyv-D-Trp.
    Type: Application
    Filed: March 5, 2004
    Publication date: September 9, 2004
    Inventors: Frank Mari, Gregg B. Fields
  • Patent number: 6096863
    Abstract: A peptide-amphiphile complex having a lipophilic portion and a peptide portion, wherein the peptide portion has a secondary structure.
    Type: Grant
    Filed: August 23, 1996
    Date of Patent: August 1, 2000
    Assignee: Regents of the University of Minnesota
    Inventors: Gregg B. Fields, Matthew V. Tirrell
  • Patent number: 5853744
    Abstract: A method for making a medical device having a biomolecule immobilized on a substrate surface is provided. The method includes: providing an immobilized biomolecule comprising a biomolecule covalently attached to a support material; attaching a photoreactive crosslinking agent to the immobilized biomolecule to form a photoreactive analog of the biomolecule; and removing the photoreactive analog of the biomolecule from the support material. The photoreactive analog of the biomolecule can then be attached to a substrate surface, such as a biomaterial that forms part of a medical device. The immobilized biomolecule may contain a peptide having an N.sup..alpha. -terminus. The photoreactive crosslinking agent is attached to the peptide at the N.sup..alpha. -terminus to form the photoreactive analog of the biomolecule. The peptide can be an adhesion peptide containing the sequence Trp-Gln-Pro-Pro-Arg-Ala-Arg-Ile. Attachment of the peptide to a substrate surface promotes cell adhesion to the surface.
    Type: Grant
    Filed: August 20, 1996
    Date of Patent: December 29, 1998
    Assignee: Regents of the University of Minnesota
    Inventors: Daniel L. Mooradian, Gregg B. Fields
  • Patent number: 5770691
    Abstract: A method of screening a sample for the presence of a matrix metalloproteinase employing discriminatory peptide substrates is provided. The method involves providing a peptide substrate of 6-14 amino acid residues containing at least one matrix metalloproteinase cleavage site. The peptide substrate contains Mca as a fluorogenic group and Lys(Dnp) as a quenching group separated by at least four amino acid residues, wherein the peptide substrate is specific for the matrix metalloproteinase of interest. The peptide substrate is combined with a sample containing at least one matrix metalloproteinase to form a mixture. The fluorescence of the mixture is monitored to determine if the matrix metalloproteinase of interest is present.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: June 23, 1998
    Assignees: Regents of the University of Minnesota, The University of Kansas Medical Center
    Inventors: Gregg B. Fields, Hideaki Nagase
  • Patent number: 5731409
    Abstract: Polypeptides are provided that have a sequence of at least about four amino acids corresponding substantially to an amino acid sequence within the triple-helical domain of Type I collagen. The polypeptides promote cell adhesion and/or cell migration. Cell culture substrates coated with the polypeptides are also provided. Prosthetic devices and methods for identifying and distinguishing cells of different types are also provided.
    Type: Grant
    Filed: October 28, 1994
    Date of Patent: March 24, 1998
    Assignee: Regents of the University of Minnesota
    Inventors: Gregg B. Fields, Leo T. Furcht, James B. McCarthy
  • Patent number: 5726243
    Abstract: A triple-helical polypeptide of the formula: ##STR1## is provided wherein: Z is Hyp or Pro; each X and Y is an amino acid such that (Gly-X-Y).sub.m is a sequence of a collagen cell adhesion site; said X and Y may be the same or different and each (Gly-X-Y) may be the same or different; O is an amino acid having a single side-chain amino group; J is an amino acid capable of acting as a chromophore; U is an amino acid; u=0 or 1; n.ltoreq.30; m.ltoreq.30; m+n.ltoreq.30; and j.gtoreq.1. Methods of making these compounds and intermediates used in the methods, are also provided.
    Type: Grant
    Filed: July 3, 1996
    Date of Patent: March 10, 1998
    Assignee: Regents of the University of Minnesota
    Inventor: Gregg B. Fields
  • Patent number: 5576419
    Abstract: A triple-helical polypeptide of the formula: ##STR1## is provided wherein: Z is Hyp or Pro; each X and Y is an amino acid such that (Gly-X-Y).sub.m is a sequence of a collagen cell adhesion site; said X and Y may be the same or different and each (Gly-X-Y) may be the same or different; O is an amino acid having a single side-chain amino group; J is an amino acid capable of acting as a chromophore; U is an amino acid; u=0 or 1; n.ltoreq.30; m.ltoreq.30; m+n.ltoreq.30; and j.gtoreq.1. Methods of making these compounds and intermediates used in the methods, are also provided.
    Type: Grant
    Filed: September 27, 1995
    Date of Patent: November 19, 1996
    Assignee: Regents of the University of Minnesota
    Inventor: Gregg B. Fields